ONCOLYTIC VIRUS

A brief history

ONCOLYTIC VIRAL IMMUNOTHERAPY.png

1800-1950s

1950s

1990s

2000s

PRESENT/FUTURE

Anecdotal evidence of cancer remission following viral infection.

Development of cell culture, description of oncolysis, clinical trials but pathogenic viruses.

Development of engineered attenuated/non-pathogenic virus to treat cancer:

- Attenuated Herpes virus mutant (Martuza et al. Science. 1991).

Virotherapy in the clinic

2015-FDA approval of T-vec: an attenuated Herpes virus expressing GMCSF.

Vyro Biotherapeutics.

First virotherapy approved for CNS tumors

THE MAIN ASPECTS THAT CONTRIBUTE TO A POOR PROGNOSIS IN PEOPLE WITH CNS TUMORS:

ONCOLYTIC VIRAL IMMUNOTHERAPY (1).png

Blood-brain barrier physiologic isolation precluding drug delivery;

Resistance of cancer stem cells to conventional therapy;

The immune-privileged isolation of the CNS (cold tumors).

Design sem nome (2).png